Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

Recruiting now · Not applicable

Conditions studied: Lymphoma

In brief

To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.

Key facts

Study ID

NCT05676450

Run by

M.D. Anderson Cancer Center

People needed

517

Starts

2023-02-23

Expected to finish

2026-08-31

Last updated by the study team

2026-05-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male/female patients who are at least 18 years of age on the day of informed consent signing.
• Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy.
• Provision of written informed consent for the study.
• Pregnant women not included
• Cognitively impaired adults are not included.

You may not qualify if…

• None

Where it is running

• MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
• Cancer Therapy and Research Center at The UT Health Science Center at San Antonio — San Antonio, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.